title: Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
authors.affiliation: University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. jcurtis@uab.edu
authors.forename: J R
authors.initials: JR
authors.lastname: Curtis
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: K G
authors.initials: KG
authors.lastname: Saag
authors.forename: N M
authors.initials: NM
authors.lastname: Patkar
authors.forename: J
authors.initials: J
authors.lastname: Kramer
authors.forename: D
authors.initials: D
authors.lastname: Shatin
authors.forename: J
authors.initials: J
authors.lastname: Allison
authors.forename: M M
authors.initials: MM
authors.lastname: Braun
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology*; D003424:Crohn Disease / Q000188:drug therapy; D016208:Databases, Factual; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D015994:Incidence; D000069285:Infliximab; D007348:Insurance, Health / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology* / Q000209:etiology; D011237:Predictive Value of Tests; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept